相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society
Hans Christoph Diener et al.
CEPHALALGIA (2021)
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer
Bassel Nazha et al.
FUTURE ONCOLOGY (2021)
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response
Ladislav Pazdera et al.
CEPHALALGIA (2021)
The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
Marta Torres-Ferrus et al.
JOURNAL OF NEUROLOGY (2021)
Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers
Elizabeth Faust et al.
NEUROLOGY AND THERAPY (2021)
Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
Stewart J. Tepper et al.
CEPHALALGIA (2020)
Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
Raffaele Ornello et al.
JOURNAL OF HEADACHE AND PAIN (2020)
A prospective real-world analysis of erenumab in refractory chronic migraine
Giorgio Lambru et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
Saad Kanaan et al.
CEPHALALGIA (2020)
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study
Ashley Alex et al.
HEADACHE (2020)
Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine
Carrie R. Houts et al.
HEADACHE (2020)
Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine
Jennifer Robblee et al.
HEADACHE (2020)
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
Fabrizio Vernieri et al.
NEUROLOGICAL SCIENCES (2020)
Long-term safety, tolerability, and efficacy of fremanezumab in migraine A randomized study
Peter J. Goadsby et al.
NEUROLOGY (2020)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
Messoud Ashina et al.
CEPHALALGIA (2018)
Assessing Physician-Patient Dialogues About Chronic Migraine During Routine Office Visits
Dawn C. Buse et al.
HEADACHE (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis
Zsolt Hepp et al.
CEPHALALGIA (2017)
Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States
J. Michael Woolley et al.
HEADACHE (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
Systematic Review of Migraine Prophylaxis Adherence and Persistence
Zsolt Hepp et al.
JOURNAL OF MANAGED CARE PHARMACY (2014)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache
Rene F. Castien et al.
CEPHALALGIA (2012)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. D. Silberstein et al.
NEUROLOGY (2012)
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Min Yang et al.
CEPHALALGIA (2011)
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability
WF Stewart et al.
NEUROLOGY (2001)
分享论文
